Clinical trial
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
NCT00219323 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00219323 |
|---|---|
| Title | Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma. |
| Official title | Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma |
| Lead sponsor | Novartis, Industry |
| Collaborators | Daiichi Sankyo Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Omalizumab |
| Enrollment | 133 |
| Start date | Nov 1, 2003 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Oct 25, 2011 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: